A Boston-based micro cap is soaring during Wednesday’s premarket after the %Biotech company announced that it has withdrew a filing for a potential stock offering after Tuesday’s closing bell.
Shares of %TransCodeTherapeutics () rallied strongly on the news as traders likely are viewing this as a non-dilutive event. Shares are currently bid up at $0.96/share (+104.26% implied open for sellers) at the time of writing. It should be an exciting session for this stock!
TransCode Therapeutics Inc is an RNA %Oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.